15 completed, 13 unknown, 12 active not recruiting, 6 recruiting. 53 Phase 3, 7 Phase 2.
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 282 | 2025-04-24 | 2026-09-25 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1046 | 2025-01-27 | 2026-11-13 |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 379 | 2024-08-13 | 2026-04-08 |
| The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Ruijin Hospital | 100 | 2024-07-29 | 2024-08-05 |
| A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Epcoritamab, Cyclophosphamide, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 900 | 2023-02-08 | 2026-09-11 |
| Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Tafasitamab, Lenalidomide - Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Incyte Corporation | 82 | 2022-12-23 | 2026-10-22 |
| A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 72 | 2022-10-08 | 2026-11-10 |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP - Diffuse Large B-Cell Lymphoma | Phase 3 | Unknown | Ruijin Hospital | 280 | 2022-03-02 | 2023-05-23 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Zilovertamab vedotin, Rituximab, Gemcitabine - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 290 | 2022-01-14 | 2026-11-03 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Incyte Corporation | 899 | 2021-05-11 | 2026-04-01 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses - Diffuse Large B-Cell Lymphoma, Elderly Patients | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 430 | 2021-03-23 | 2022-08-26 |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Rituxumab - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 270 | 2021-02-23 | 2026-10-02 |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 483 | 2021-01-13 | 2026-11-03 |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) acalabrutinib, placebo, Prednisone - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Acerta Pharma BV | 611 | 2020-10-08 | 2026-10-13 |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Brentuximab vedotin, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 240 | 2020-08-20 | 2026-10-21 |
| Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo - Diffuse Large B-cell Lymphoma | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 423 | 2020-05-21 | 2026-04-08 |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | Hoffmann-La Roche | 270 | 2020-02-07 | 2025-12-22 |
Showing 20 of 53. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (53) · Lymphoma, Non-Hodgkin (7) · Lymphoma (5) · Lymphoma, Mantle-Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Follicular (4) · Recurrence (4) · Hematologic Neoplasms (3) · Lymphoma, B-Cell (3) · Waldenstrom Macroglobulinemia (3) · Hodgkin Disease (2) · Multiple Myeloma (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bronchiolitis Obliterans Syndrome (1)
Hemic and Lymphatic Diseases (53) · Immune System Diseases (53) · Immunoproliferative Disorders (53) · Neoplasms by Histologic Type (53) · Lymphatic Diseases (52) · Lymphoproliferative Disorders (52) · Neoplasms (51) · Lymphoma, B-Cell (50) · Lymphoma (48) · Lymphoma, Non-Hodgkin (46) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Hematologic Diseases (6) · Leukemia (5)
Rituximab (28) · Cyclophosphamide (13) · Doxorubicin (12) · Prednisone (12) · Vincristine (12) · Gemcitabine (9) · Lenalidomide (9) · Oxaliplatin (8) · Bendamustine Hydrochloride (5) · Etoposide (4) · polatuzumab vedotin (4) · tafasitamab (4) · Cyclosporine (2) · Cyclosporins (2) · Granulocyte Colony-Stimulating Factor (2)
Genmab (4) · Hoffmann-La Roche (4) · Incyte Corporation (3) · Merck Sharp & Dohme LLC (3) · Ruijin Hospital (3) · Fondazione Italiana Linfomi - ETS (2) · Fred Hutchinson Cancer Center (2) · Novartis Pharmaceuticals (2) · Wuhan University (2) · Acerta Pharma BV (1) · Asan Medical Center (1) · CTI BioPharma (1) · Celgene (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chipscreen Biosciences, Ltd. (1)
China (28) · United States (24) · Italy (21) · Poland (20) · Australia (19) · South Korea (19) · Spain (19) · France (18) · United Kingdom (18) · Canada (16) · Czechia (14) · Belgium (13) · Germany (13) · Israel (13) · Turkey (Türkiye) (13)
Brenda Sandmaier (2) · Adrian Kilcoyne, MD (1) · Elena N Parovichnikova, MD PhD (1) · Francesco Merli, Dott. (1) · Heidi Mocikova, M.D., Ph.D. (1) · Jeremy S Abramson (1) · Jianda Hu, Prof. (1) · Jifeng Feng, M.D. (1)
PMID 32499241, PMID 32817282, PMID 42699559, PMID 21495023, PMID 27093976, PMID 28381416, PMID 28668386, PMID 29253068, PMID 30341058, PMID 30617197, PMID 30770362, PMID 31053601, PMID 31126528, PMID 31248843, PMID 31879945, PMID 31978225, PMID 32250167, PMID 32505213, PMID 33054054, PMID 33107145, PMID 33278600, PMID 33651099, PMID 33683917, PMID 34323957, PMID 34323958, PMID 34634256, PMID 34687398, PMID 34780623, PMID 34904799, PMID 35710733, PMID 35726803, PMID 35962459, PMID 36626583, PMID 36740991, PMID 37369099, PMID 37702406, PMID 37864313, PMID 38498084, PMID 38843483, PMID 39319495, PMID 39550172, PMID 39772655, PMID 39962481, PMID 40085955, PMID 40749164, PMID 40991874, PMID 40993016, PMID 40997297, PMID 41056515, PMID 42018318
2023 (4), P30CA015704 (2), 2008 (1), 2014 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1), P01CA018029 (1), P01CA078902 (1), U10CA180821 (1)